Phibro Animal Health Corporation

As of June 30, 2026, Phibro Animal Health Corporation Class A carries a market capitalization of 1.11B, placing it among publicly traded companies globally. Its enterprise value stands at 1.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Phibro Animal Health Corporation Class A's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Phibro Animal Health Corporation Class A has 40.56M shares outstanding.

As of June 30, 2026, Phibro Animal Health Corporation Class A trades at a trailing price-to-earnings ratio of 12.73. The price-to-sales ratio is 0.84, and the price-to-book ratio stands at 3.29.

As of June 30, 2026, Phibro Animal Health Corporation Class A trades at an EV/EBITDA multiple of 8.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Phibro Animal Health Corporation Class A trades at an EV/FCF ratio of 19.58, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.73B versus a market cap of 1.11B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Phibro Animal Health Corporation Class A maintains a current ratio of 2.96, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 204.62, indicating elevated leverage, while an interest coverage ratio of 5.58 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Phibro Animal Health Corporation Class A posted a return on equity (ROE) of 29.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.86, useful for judging operating efficiency across full business cycles. The company generates approximately 529,924.95 in revenue per employee across its workforce of 2,507.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.05 indicates how many times Phibro Animal Health Corporation Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Phibro Animal Health Corporation Class A recorded 32.93M in income tax expense. That works out to an effective tax rate of 27.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 120.22M, leaving 87.28M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 1, 2026, Phibro Animal Health Corporation Class A's stock has gained approximately 6.45% over the past 52 weeks. The 50-day moving average sits at 29.40, while the 200-day moving average is 35.32.

Over the twelve months ended June 30, 2026, Phibro Animal Health Corporation Class A generated 1.33B in revenue and converted that into 87.28M in net income, yielding earnings per share of 2.13. EBITDA reached 215.25M, while operating income came in at 170.15M.

As of June 30, 2026, Phibro Animal Health Corporation Class A holds 71.77M in cash and equivalents against 690.41M in total debt, resulting in a net debt position of 587.65M. Total book value stands at 337.41M, with working capital of 541.84M providing operational flexibility.

Phibro Animal Health Corporation Class A produced 60.36M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Phibro Animal Health Corporation Class A posted a gross margin of 33.76, reflecting its pricing power and cost economics. The operating margin of 12.81 and net profit margin of 6.57 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Phibro Animal Health Corporation Class A paid dividends of 0.42 per share. The dividend payout ratio of 19.52 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.38, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Phibro Animal Health Corporation Class A shareholders.

As of June 30, 2026, Phibro Animal Health Corporation Class A has an Altman Z-Score of 3.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.